PsychoGenics, a Paramus, NJ-based company which specializes in AI-enabled phenotypic drug discovery, received $3M in SBIR Grant by NIMH.
The company intends to use the amount to develop eCube®, its proprietary AI-enabled EEG platform, along with its machine learning tools, to identify novel applications for existing drugs targeting rare diseases.
Led by CEO Emer Leahy, and CIO/CTO Daniela Brunner, PsychoGenics is a biotechnology company dedicated to advancing drug discovery that has empowered the translation of rodent behavioral and physiological responses into high-throughput and high-content phenotyping. Its drug discovery platforms SmartCube®, NeuroCube®, PhenoCube®, and eCube® have been used in shared-risk partnerships with pharmaceutical companies, including Sunovion, Roche and Karuna, resulting in the discovery of several novel compounds now in advanced preclinical development and clinical trials. PsychoGenics’ capabilities also include standard behavioral testing, electrophysiology, translational EEG, molecular biology, microdialysis, and quantitative immunohistochemistry.
In addition, the company offers a variety mouse models to support research in areas such as Huntington’s disease, autism spectrum disorders, pain, psychosis/schizophrenia, depression, PTSD, Alzheimer’s disease, Parkinson’s disease, neuromuscular disorders and seizure disorders.
FinSMEs
28/08/2024